Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Liu

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Nature Biomedical Engineering|August 13, 2021
Control of the activity of CAR-T cells within tumours via focused ultrasoundYiqian Wu, Yahan Liu, Ziliang Huang, et al.
Circulation|November 21, 2013
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trialMichael J Koren, Robert P Giugliano, Frederick J Raal, et al.
The New England Journal of Medicine|March 18, 2017
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseMarc S Sabatine, Robert P Giugliano, Anthony C Keech, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2023
WITHDRAWN: I feel your pain: Higher empathy is associated with higher posterior default mode network activityValeria Oliva, Gabriel Riegner, Jon Dean, et al.
Pain|December 11, 2024
I feel your pain: higher empathy is associated with higher posterior default mode network activityValeria Oliva, Gabriel Riegner, Jon Dean, et al.
Lancet (London, England)|November 13, 2012
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 studyRobert P Giugliano, Nihar R Desai, Payal Kohli, et al.
Nature Communications|August 10, 2020
Distinct thalamocortical network dynamics are associated with the pathophysiology of chronic low back painYiheng Tu, Zening Fu, Cuiping Mao, et al.
Nature Communications|August 27, 2020
Author Correction: Distinct thalamocortical network dynamics are associated with the pathophysiology of chronic low back painYiheng Tu, Zening Fu, Cuiping Mao, et al.
European Heart Journal|March 7, 2014
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trialsEvan A Stein, Robert P Giugliano, Michael J Koren, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 PandemicR Daniel Meyer, Bohdana Ratitch, Marcel Wolbers, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Nature Biomedical Engineering|August 13, 2021
Control of the activity of CAR-T cells within tumours via focused ultrasoundYiqian Wu, Yahan Liu, Ziliang Huang, et al.
Circulation|November 21, 2013
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trialMichael J Koren, Robert P Giugliano, Frederick J Raal, et al.
The New England Journal of Medicine|March 18, 2017
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseMarc S Sabatine, Robert P Giugliano, Anthony C Keech, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2023
WITHDRAWN: I feel your pain: Higher empathy is associated with higher posterior default mode network activityValeria Oliva, Gabriel Riegner, Jon Dean, et al.
Pain|December 11, 2024
I feel your pain: higher empathy is associated with higher posterior default mode network activityValeria Oliva, Gabriel Riegner, Jon Dean, et al.
Lancet (London, England)|November 13, 2012
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 studyRobert P Giugliano, Nihar R Desai, Payal Kohli, et al.
Nature Communications|August 10, 2020
Distinct thalamocortical network dynamics are associated with the pathophysiology of chronic low back painYiheng Tu, Zening Fu, Cuiping Mao, et al.
Nature Communications|August 27, 2020
Author Correction: Distinct thalamocortical network dynamics are associated with the pathophysiology of chronic low back painYiheng Tu, Zening Fu, Cuiping Mao, et al.
European Heart Journal|March 7, 2014
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trialsEvan A Stein, Robert P Giugliano, Michael J Koren, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 PandemicR Daniel Meyer, Bohdana Ratitch, Marcel Wolbers, et al.
Pageof 6